Debra Bell
The University of Melbourne(AU)Mayo Clinic in Arizona(US)
Publications by Year
Research Areas
Cancer Genomics and Diagnostics, Ovarian cancer diagnosis and treatment, RNA modifications and cancer, PARP inhibition in cancer therapy, DNA Repair Mechanisms
Most-Cited Works
- → Integrated genomic analyses of ovarian carcinoma(2011)8,053 cited
- → Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma(2018)282 cited
- → Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses(2020)38 cited
- → Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas(2017)26 cited
- → BRCA1 secondary splice-site mutations drive exon-skipping and PARP inhibitor resistance(2024)24 cited
- → Correlation of molecular markers including mutations with clinical outcomes in advanced non small cell lung cancer (NSCLC) patients (pts) treated with gefitinib, chemotherapy or chemotherapy and gefitinib in IDEAL and INTACT clinical trials(2005)24 cited
- → When ascites is not ascites(2008)15 cited
- → Question(1979)9 cited
- → Borderline Tumors of the Ovary(2000)6 cited
- → Small-scale mutations are infrequent as mechanisms of resistance in post-PARP inhibitor tumour samples in high grade serous ovarian cancer(2023)5 cited